Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ: AMLX · Real-Time Price · USD

21.43

-0.20 (-0.92%)

At close: Aug 17, 2026, 4:00 PM EDT

24.70

+3.27 (15.26%)

After-hours: Aug 17, 2026, 4:12 PM EDT

Amylyx Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	49.33	226.65	77.39	170.2	62.53	50.19
Short-Term Investments	201.43	90.33	99.11	201.16	284.42	45.93
Cash & Short-Term Investments	250.76	316.98	176.5	371.36	346.95	96.12
Cash Growth	38.67%	79.59%	-52.47%	7.04%	260.96%	646.43%
Accounts Receivable	-	0.09	0.45	40.05	15.31	-
Other Receivables	0.5	0.1	0.1	0.5	0.5	-
Receivables	0.5	0.19	0.55	40.55	15.81	-
Inventory	-	-	-	38.32	9.77	-
Prepaid Expenses	5.08	6.5	12.38	14.43	9.61	5.39
Other Current Assets	-	-	-	-	-	3.44
Total Current Assets	256.34	323.67	189.43	464.67	382.13	104.95
Property, Plant & Equipment	4.74	5.49	2.73	6.41	8.14	0.47
Other Long-Term Assets	3.49	3.48	1.47	46.38	1.19	0.19
Total Assets	264.56	332.65	193.63	517.45	391.45	105.61

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	5.53	3.52	2.94	22.06	6.26	4.37
Accrued Expenses	14.61	17.91	23.95	57.72	38.31	13.02
Current Portion of Leases	1.01	1.26	1.52	2.26	2.04	-
Total Current Liabilities	21.15	22.69	28.41	82.04	46.61	17.4
Long-Term Leases	4.25	4.7	0.46	1.98	4.24	-
Other Long-Term Liabilities	-	-	-	-	-	0.04
Total Liabilities	25.4	27.39	28.87	84.02	50.85	17.43

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	1,075	1,056	771.54	738.18	694.91	4.67
Retained Earnings	-836.13	-751.43	-606.69	-304.95	-354.22	-155.85
Comprehensive Income & Other	0.02	0.4	-0.09	0.2	-0.09	0.01
Total Common Equity	239.17	305.26	164.77	433.43	340.61	-151.17
Shareholders' Equity	239.17	305.26	164.77	433.43	340.61	88.18
Total Liabilities & Equity	264.56	332.65	193.63	517.45	391.45	105.61

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	5.26	5.96	1.98	4.24	6.28	-
Net Cash (Debt)	245.51	311.02	174.52	367.13	340.67	96.12
Net Cash Growth	40.40%	78.22%	-52.46%	7.77%	254.43%	739.31%
Net Cash Per Share	2.31	3.29	2.56	5.25	5.82	14.59
Filing Date Shares Outstanding	111.42	110.54	88.6	67.78	66.72	57.86
Total Common Shares Outstanding	111.37	109.88	68.63	66.51	66.51	7.02
Working Capital	235.19	300.98	161.03	382.62	335.52	87.56
Book Value Per Share	2.15	2.78	2.40	6.52	5.12	-21.53
Tangible Book Value	239.17	305.26	164.77	433.43	340.61	-151.17
Tangible Book Value Per Share	2.15	2.78	2.40	6.52	5.12	-21.53
Machinery	-	1.69	1.92	3.55	2.17	0.34
Construction In Progress	-	0.02	0.22	0.59	0.8	0.14
Leasehold Improvements	-	0.15	0.18	0.18	0.18	0.05

SEC Filings: 10-K · 10-Q